Search results for "PLACEBO"

showing 10 items of 704 documents

Prospective Comparison on Cardiac Iron and Liver Iron by MR In Thalassemia Major Patients Treated with Combination Deferipron–Desferrioxamine Versus …

2010

Abstract Abstract 5164 Introduction: Using T2* MR a randomised placebo controlled study from Sardinia demonstrated combination therapy with deferiprone and desferrioxamine (DFP+DFO) significantly more effective than DFO in improving myocardial iron. One non-randomised study from Sardinia and one observational study from Greece seem to confirm for DFP+DFO therapy the most rapid clearance of cardiac iron. No data are available in literature about prospective comparisons on cardiac iron and function and liver iron in TM patients treated with DFP+DFO versus DFP and DFO in monotherapy. The aim of this multi-centre study was to assess prospectively in a large clinical setting the efficacy of the …

medicine.medical_specialtyCombination therapybusiness.industryThalassemiaImmunologyUrologyPlacebo-controlled studyCell BiologyHematologymedicine.diseaseBiochemistryDeferipronSurgeryBiventricular functionchemistry.chemical_compoundchemistrymedicineCardiac ironLiver ironDeferipronebusiness
researchProduct

Human corticotropin-releasing hormone and thyrotropin-releasing hormone modulate the hypercapnic ventilatory response in humans

1996

Human corticotropin-releasing hormone (hCRH) and thyrotropin-releasing hormone (TRH) are known to stimulate ventilation after i.v. administration in humans. In a placebo-controlled, single-blind study we aimed to clarify if both peptides act by altering central chemosensitivity. Two subsequent CO2-rebreathing tests were performed in healthy young volunteers. During the first test 0.9% NaCl was given i.v.; during the second test 200 micrograms of hCRH (n = 12) or 400 micrograms of TRH (n = 6) was administered i.v. Nine subjects received 0.9% NaCl i.v. during both rebreathing manoeuvres. The CO2-response curves for the two tests were compared within the same subject. In the hCRH group a marke…

medicine.medical_specialtyCorticotropin-Releasing HormoneClinical BiochemistryThyrotropin-releasing hormonePeptide hormoneBiochemistryHypercapniaPlacebos03 medical and health sciencesCorticotropin-releasing hormone0302 clinical medicineTachycardiaInternal medicineFlushingmedicineHumansSingle-Blind MethodRespiratory systemThyrotropin-Releasing HormoneLung function030304 developmental biology0303 health sciencesbusiness.industryRespirationGeneral MedicineCarbon DioxideRespiratory Function TestsEndocrinologyBreathingbusiness030217 neurology & neurosurgeryHormoneEuropean Journal of Clinical Investigation
researchProduct

Effects of the Combination of Candesartan plus Captopril in Elderly Patients with Anterior Myocardial Infarction

2000

Objective: To verify the feasibility, tolerability and efficacy of the combination of captopril (75 mg/day) and candesartan (8 mg/day) in early postinfarction phases of not thrombolysed and unreperfused anterior acute myocardial infarction (AMI) in elderly patients. Design and Patients: 71 patients (aged >65 years) hospitalised for anterior AMI were randomised in a double-blind manner into two groups: group A included 35 patients who received captopril 75 mg/day within 3 days of admission plus candesartan 4mg, as a first dose, and 8 mg/day successively; group B included 36 patients who received captopril 75 mg/day and placebo. 90 days after admission, patients underwent echocardiography to …

medicine.medical_specialtyCreatinineEjection fractionbusiness.industryCaptoprilGeneral MedicinePlacebomedicine.diseaseCandesartanchemistry.chemical_compoundBlood pressurechemistryTolerabilityInternal medicineCardiologyMedicinePharmacology (medical)Myocardial infarctionbusinessmedicine.drugClinical Drug Investigation
researchProduct

Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis

2019

Objective We aimed to assess the safety of topical non-steroidal anti-inflammatory drugs (NSAIDs) in the management of osteoarthritis (OA) in a systematic review and meta-analysis of randomized, placebo-controlled trials. Methods A comprehensive literature search was undertaken in the MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and Scopus electronic databases. Randomized, double-blind, placebo-controlled, parallel-group trials that assessed adverse events (AEs) with topical NSAIDs in patients with OA were eligible for inclusion. Authors and/or study sponsors were contacted to obtain the full report of AEs. The primary outcomes were overall severe and serious AEs, as w…

medicine.medical_specialtyDICLOFENAC SODIUM GELDiclofenacDrug-Related Side Effects and Adverse ReactionsMedDRAVEHICLE TDT 064MEDLINEOsteoarthritisKNEE OSTEOARTHRITISAdministration CutaneousPlaceboLONG-TERM USE03 medical and health sciencesDOUBLE-BLIND0302 clinical medicinePharmacotherapyInternal medicineOsteoarthritisHumansMedicinePharmacology (medical)030212 general & internal medicineAdverse effectRandomized Controlled Trials as Topicbusiness.industryAnti-Inflammatory Agents Non-SteroidalTRANSFERSOME GELOdds ratiomedicine.diseaseEFFICACYRANDOMIZED CLINICAL-TRIALORAL CELECOXIBTreatment OutcomeMeta-analysisSystematic ReviewGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryTASK-FORCE
researchProduct

Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone Turnover

2005

We studied clinical performance of serum TRACP 5b and other bone turnover markers, including S-CTX, U-DPD, S-PINP, S-BALP, and S-OC, for monitoring alendronate treatment. TRACP 5b had higher clinical sensitivity, area under the ROC curve, and signal-to-noise ratio than the other markers. INTRODUCTION: The purpose of this study was to compare the clinical performance of serum TRACP 5b (S-TRACP5b) with that of other markers of bone turnover in the monitoring of alendronate treatment. MATERIALS AND METHODS: This double-blinded study included 148 healthy postmenopausal women that were randomly assigned into two groups: one receiving 5 mg alendronate daily (n=75) and the other receiving placebo …

medicine.medical_specialtyDeoxypyridinolineEndocrinology Diabetes and MetabolismAcid PhosphataseUrologyPlaceboBone resorptionBone remodelingchemistry.chemical_compoundDouble-Blind MethodOsteogenesisInternal medicinemedicineVitamin D and neurologyHumansOrthopedics and Sports MedicineVitamin DAlendronateBone Density Conservation AgentsReceiver operating characteristicbiologyTartrate-Resistant Acid Phosphatasebusiness.industryAlendronic acidMiddle AgedIsoenzymesPostmenopauseEndocrinologychemistryOsteocalcinbiology.proteinCalciumFemaleDrug MonitoringbusinessBiomarkersmedicine.drugJournal of Bone and Mineral Research
researchProduct

Effect of acetyl-l-carnitine in the treatment of diabetic peripheral neuropathy : A systematic review and meta-analysis

2017

Background/aim: Deficiency of acetyl-L-carnitine (ALC) and L-carnitine (LC) appears to play a role in peripheral diabetic neuropathy, although the evidence in humans is still limited. We conducted a systematic review and meta-analysis investigating the effect of ALC on pain and electromyographic parameters in people with diabetic neuropathy. Methods: A literature search in major databases, without language restriction, was undertaken. Eligible studies were randomized controlled trials (RCTs) or pre-and post-test studies. The effect of ALC supplementation on pain perception and electromyographic parameters in patients with diabetic neuropathy was compared vs. a control group (RCTs). The effe…

medicine.medical_specialtyDiabetic neuropathyDiabetePlaceboNerve conduction velocitylaw.inventionRATS03 medical and health sciencesGLUTAMATE0302 clinical medicineRandomized controlled triallawDiabetes mellitusMedicineQUALITYMeta-analysi030212 general & internal medicineUlnar nerveAdverse effectbusiness.industryDiabetesNERVE GROWTH-FACTORPAINmedicine.diseaseAcetyl-L-carnitine3. Good healthSurgeryNeuropathyAcetyl-L-carnitine; Diabetes; Meta-analysis; Neuropathy; Gerontology; Geriatrics and GerontologyMeta-analysisPeripheral neuropathyAnesthesia3121 General medicine internal medicine and other clinical medicineGeriatrics and GerontologybusinessGerontology030217 neurology & neurosurgeryCLINICAL-TRIALS
researchProduct

Long-term effects of graduated compression stockings on cardiorespiratory performance

2015

ABSTRACT: The use of graduated compression stockings (GCS) in sport has been increasing in the last years due to their potential positive effects for athletes. However, there is little evidence to support whether these types of garments actually improve cardiorespiratory performance. The aim of this study was to examine the cardiorespiratory responses of GCS during running after three weeks of regular use. Twenty recreational runners performed three tests on different days: test 1) ¿ a 5-min maximal effort run in order to determine the participants¿ maximal aerobic speed; and tests 2) and 3) ¿ a fatigue running test of 30 minutes at 80% of their maximal aerobic speed with either GCS or PLAC…

medicine.medical_specialtyDidáctica de la Expresión CorporalPhysiologyExercise testHeart raterespiratory parametersexercise testOxygen pulseOxygen consumptionPhysical Therapy Sports Therapy and RehabilitationMedicina esportivaCarbon dioxide productionPlaceboRunningPhysiology (medical)Heart raterunningheart rateMedicineCorOrthopedics and Sports Medicinelcsh:Sports medicinelcsh:QH301-705.5business.industryCardiorespiratory fitnessoxygen consumptionGraduated compression stockingslcsh:Biology (General)PulmonsphysiologyPhysical therapyOriginal Articlelcsh:RC1200-1245businessRespiratory minute volumeRespiratory parametersBiology of Sport
researchProduct

High- versus low-dose ACE inhibition in chronic heart failure

1998

Abstract Objectives. To determine dose-related clinical and neurohumoral effects of angiotensin-converting enzyme (ACE) inhibitors in patients with chronic heart failure (CHF), we conducted a double-blind, placebo-controlled, randomized study of three doses (2.5 mg, 5 mg and 10 mg) of the long-acting ACE inhibitor imidapril. Background. The ACE inhibitors have become a cornerstone in the treatment of CHF, but whether high doses are more effective than low doses has not been fully elucidated, nor have the mechanisms involved in such a dose-related effect. Methods. In a parallel group comparison, the effects of three doses of imidapril were examined. We studied 244 patients with mild to moder…

medicine.medical_specialtyDigoxinbiologybusiness.industryPlacebo-controlled studyAngiotensin-converting enzymemedicine.diseasePlaceboEndocrinologyImidaprilInternal medicineHeart failureACE inhibitorbiology.proteinCardiologyMedicineEnalaprilCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of the American College of Cardiology
researchProduct

Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration

2018

Abstract Fibrates are drugs that reduce triglycerides, elevate high-density lipoproteins, as well as decrease small, dense LDL particles. The results of a study have recently been published by the Cochrane Collaboration on fibrates efficacy and safety in the primary prevention of cardiovascular disease. This study includes a systematic review and a meta-analysis of 6 studies (16,135 patients) that evaluated the clinical benefits of fibrates compared to placebo use or other lipid-lowering drugs. This review showed evidence of a protective effect of the fibrates compared with placebo as regards a reduction 16% of a compound objective of death due to cardiovascular disease, non-fatal myocardia…

medicine.medical_specialtyDiseasePlacebochemistry.chemical_compoundInternal medicinePrimary preventionmedicineHumansMyocardial infarctionHypolipidemic AgentsGeneral Environmental ScienceCreatinineCochrane collaborationbusiness.industryFibric AcidsGeneral EngineeringDiabetic retinopathymedicine.diseaseLipidsPrimary PreventionTotal mortalitychemistryCardiovascular DiseasesCreatinineGeneral Earth and Planetary SciencesDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

Efficacy of amoxicillin and amoxicillin/clavulanic acid in the prevention of infection and dry socket after third molar extraction: a systematic revi…

2016

Background: Prophylactic use of amoxicillin and amoxicillin/clavulanic acid, although controversial, is common in routine clinical practice in third molar surgery. Material and Methods: Our objective was to assess the efficacy of prophylactic amoxicillin with or without clavulanic acid in reducing the incidence of dry socket and/or infection after third molar extraction. We conducted a systematic review and meta-analysis consulting electronic databases and references in retrieved articles. We included double-blind placebo-controlled randomized clinical trials published up to June 2015 investigating the efficacy of amoxicillin with or without clavulanic acid on the incidence of the aforement…

medicine.medical_specialtyDry SocketOdontologíaReviewTooth ExfoliationPlaceboAmoxicillin-Potassium Clavulanate Combinationlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawClavulanic acidInternal medicinemedicineHumansGeneral DentistryInfection Control030219 obstetrics & reproductive medicineAmoxicillin/clavulanic acidbusiness.industryAmoxicillin030206 dentistryAmoxicillinmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgeryAnti-Bacterial AgentsDry socketOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASNumber needed to treatSurgeryMolar ThirdAmoxicillin-Potassium Clavulanate CombinationOral Surgerybusinessmedicine.drug
researchProduct